BR112022014160A2 - Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau - Google Patents
Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tauInfo
- Publication number
- BR112022014160A2 BR112022014160A2 BR112022014160A BR112022014160A BR112022014160A2 BR 112022014160 A2 BR112022014160 A2 BR 112022014160A2 BR 112022014160 A BR112022014160 A BR 112022014160A BR 112022014160 A BR112022014160 A BR 112022014160A BR 112022014160 A2 BR112022014160 A2 BR 112022014160A2
- Authority
- BR
- Brazil
- Prior art keywords
- zinc finger
- transcription factors
- finger protein
- protein transcription
- tau expression
- Prior art date
Links
- 102000038627 Zinc finger transcription factors Human genes 0.000 title abstract 2
- 108091007916 Zinc finger transcription factors Proteins 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964501P | 2020-01-22 | 2020-01-22 | |
| PCT/US2021/014780 WO2021151012A1 (en) | 2020-01-22 | 2021-01-22 | Zinc finger protein transcription factors for repressing tau expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014160A2 true BR112022014160A2 (pt) | 2022-09-13 |
Family
ID=74661487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014160A BR112022014160A2 (pt) | 2020-01-22 | 2021-01-22 | Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230242602A1 (enExample) |
| EP (1) | EP4093754A1 (enExample) |
| JP (1) | JP2023511908A (enExample) |
| KR (1) | KR20220131273A (enExample) |
| CN (1) | CN115210251A (enExample) |
| AR (1) | AR121118A1 (enExample) |
| AU (1) | AU2021209699A1 (enExample) |
| BR (1) | BR112022014160A2 (enExample) |
| CA (1) | CA3168805A1 (enExample) |
| IL (1) | IL294535A (enExample) |
| MX (1) | MX2022008953A (enExample) |
| TW (1) | TW202134288A (enExample) |
| UY (1) | UY39036A (enExample) |
| WO (1) | WO2021151012A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110214184B (zh) | 2016-12-01 | 2024-07-02 | 桑格摩生物治疗股份有限公司 | τ蛋白调节剂以及用于其递送的方法和组合物 |
| IL326834A (en) | 2018-10-02 | 2026-04-01 | Sangamo Therapeutics Inc | Artificial zinc finger protein transcription factors repressing mapt expression for the prevention and/or treatment of tauopathies |
| WO2021067871A1 (en) * | 2019-10-02 | 2021-04-08 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing alpha-synuclein expression |
| WO2025193848A1 (en) * | 2024-03-13 | 2025-09-18 | Sangamo Therapeutics, Inc. | Delivery of tau repressors using the blood-brain barrier penetrant capsid |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| JP4012243B2 (ja) | 1994-01-18 | 2007-11-21 | ザ スクリップス リサーチ インスティチュート | 亜鉛フィンガータンパク質誘導体およびそのための方法 |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| CA2196419C (en) | 1994-08-20 | 2007-08-21 | Yen Choo | Improvements in or relating to binding proteins for recognition of dna |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| DE69942334D1 (de) | 1998-03-02 | 2010-06-17 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
| WO2001053480A1 (en) | 2000-01-24 | 2001-07-26 | Sangamo Biosciences, Inc. | Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| CA2725773C (en) | 2008-05-28 | 2017-12-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
| EP2566972B1 (en) | 2010-05-03 | 2020-01-15 | Sangamo Therapeutics, Inc. | Compositions for linking zinc finger modules |
| CA2920899C (en) | 2013-08-28 | 2023-02-28 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
| EP3929279A1 (en) | 2014-03-18 | 2021-12-29 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
| WO2017011556A1 (en) * | 2015-07-13 | 2017-01-19 | The General Hospital Corporation | Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof |
| JP7012650B2 (ja) | 2016-02-02 | 2022-01-28 | サンガモ セラピューティクス， インコーポレイテッド | Ｄｎａ結合ドメインと切断ドメインとを連結するための組成物 |
| IL264792B2 (en) | 2016-08-24 | 2023-10-01 | Sangamo Therapeutics Inc | Engineered target-specific zinc-finger nucleases |
| CN110214184B (zh) * | 2016-12-01 | 2024-07-02 | 桑格摩生物治疗股份有限公司 | τ蛋白调节剂以及用于其递送的方法和组合物 |
| KR20210069692A (ko) | 2018-10-02 | 2021-06-11 | 상가모 테라퓨틱스, 인코포레이티드 | 조작된 유전자 조정제 |
| IL326834A (en) | 2018-10-02 | 2026-04-01 | Sangamo Therapeutics Inc | Artificial zinc finger protein transcription factors repressing mapt expression for the prevention and/or treatment of tauopathies |
-
2021
- 2021-01-22 TW TW110102602A patent/TW202134288A/zh unknown
- 2021-01-22 US US17/791,395 patent/US20230242602A1/en active Pending
- 2021-01-22 UY UY0001039036A patent/UY39036A/es not_active Application Discontinuation
- 2021-01-22 BR BR112022014160A patent/BR112022014160A2/pt not_active Application Discontinuation
- 2021-01-22 AU AU2021209699A patent/AU2021209699A1/en active Pending
- 2021-01-22 MX MX2022008953A patent/MX2022008953A/es unknown
- 2021-01-22 AR ARP210100163A patent/AR121118A1/es unknown
- 2021-01-22 EP EP21706102.7A patent/EP4093754A1/en active Pending
- 2021-01-22 CA CA3168805A patent/CA3168805A1/en active Pending
- 2021-01-22 IL IL294535A patent/IL294535A/en unknown
- 2021-01-22 KR KR1020227028167A patent/KR20220131273A/ko active Pending
- 2021-01-22 CN CN202180010601.9A patent/CN115210251A/zh active Pending
- 2021-01-22 JP JP2022544353A patent/JP2023511908A/ja not_active Ceased
- 2021-01-22 WO PCT/US2021/014780 patent/WO2021151012A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| UY39036A (es) | 2021-08-31 |
| JP2023511908A (ja) | 2023-03-23 |
| MX2022008953A (es) | 2022-08-15 |
| IL294535A (en) | 2022-09-01 |
| WO2021151012A1 (en) | 2021-07-29 |
| CN115210251A (zh) | 2022-10-18 |
| KR20220131273A (ko) | 2022-09-27 |
| EP4093754A1 (en) | 2022-11-30 |
| AR121118A1 (es) | 2022-04-20 |
| US20230242602A1 (en) | 2023-08-03 |
| AU2021209699A1 (en) | 2022-07-21 |
| CA3168805A1 (en) | 2021-07-29 |
| TW202134288A (zh) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121118A1 (es) | Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau | |
| BR112022012230A2 (pt) | Variantes de progranulina | |
| ECSP20081591A (es) | Proteínas de fusión que comprenden progranulina | |
| ECSP19043710A (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas | |
| BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
| GEAP202114964A (en) | ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF | |
| CR8978A (es) | Proteinas de fusion de dominio de union | |
| MX2020001855A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides. | |
| MX392158B (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| CL2018002430A1 (es) | Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas | |
| CO6390113A2 (es) | Composición farmacéutica | |
| BR112018006873A2 (pt) | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| CL2023000853A1 (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| EA202092305A1 (ru) | Соединения в качестве модуляторов сигнализации tlr2 | |
| MX2021011596A (es) | Compuestos y composiciones como moduladores de se?alizacion tlr. | |
| EA201992688A1 (ru) | Средства, пути применения и способы лечения | |
| BR112022021743A2 (pt) | Compostos e métodos direcionando a interleucina-34 | |
| CY1124821T1 (el) | Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ | |
| MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
| EA201990593A1 (ru) | Непрерывный способ для снижения гетерогенности терапевтического белка | |
| BR112022006734A2 (pt) | Moduladores atf6 e usos dos mesmos | |
| MX388366B (es) | Composiciones para tratar enfermedades neurodegenerativas. | |
| BR112022004475A2 (pt) | Proteínas de fusão nkg2d e usos das mesmas | |
| MX2020010301A (es) | Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |